Can't compare the old team with the new one. They are worlds apart. The idea that we can buy shares in a company a few months out from completing a Phase 2 trial which if successful would give immediate access to the EU and leave us one step from the US in a wound care field which is crying out for new innovations and all for just a $40m market cap is pretty crazy.
Biotech Daily, page-4
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
